tyrosine kinase inhibitor - Globe Thesis

Keyword [tyrosine kinase inhibitor] Result: 101 - 120 \| Page: 6 of 10
101.	Sequential Therapy After The Failure Of Anti-angiogenesis Therapy In Advanced Renal Cell Carcinoma: A Meta Analysis
102.	Efficacy Of 2nd Generation’s TKI In Treatment Of Imatinib Resistant Or Intolerant Chronic Myelogenous Leukemia
103.	Clinical Study Of Modified Xiaoji Decoction Combines With Cytokine Induced Killer Cells And Erlotinib In The Treating Of Advanced Non-small Cell Lung Cancer
104.	Study Of Bruton’s Tyrosine Kinase Inhibitor In Peripheral T-Cell Lymphomas Cell Lines Proliferation
105.	Hepatocyte Growth Factor Reduces Sensitivity To The Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor, Gefitinib,in Lung Adenocarcinoma Cells Harboring Wild-TypeEGFR
106.	Efficiency And Safety Of Intercalated Treatment Of Icotinib With Chemotherapy In Patients Undergoing Resection Of EGFR Mutation-positive Non-small Cell Lung Cancer
107.	Efficacy And Safety Of EGFR Tyrosine Kinase Inhibitor Monotherapy With Docetaxel Monotherapy In Previously Treated Advanced Non-Small-Cell Lung Cancer: A Meta-analysis
108.	Synthesis Of Tyrosine Kinase Inhibitor Ureide Connected Indole-Benzimidazole Compounds
109.	Synthesis Of 2-Indolone Carbamido Connected Benzimidazole Tyrosine Kinase Inhibitors
110.	Expression And Molecular Mechanism Of Oct4 In The Resistance Of Non-small Cell Lung Cancer To Gefitinib
111.	Circulating Plasma MicroRNAs As Potential Markers To Identify EGFR Mutation Status And To Monitor Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor Treatment In Patients With Advanced Non-small Cell Lung Cancer
112.	MZH29 Is A Novel Potent Inhibitor That Overcomes Drug Resistance FLT3 Mutations In Acute Myeloid Leukemia
113.	The Therapeutic Effect Analysis Of Tyrosine Kinase Inhibitor And Chemotherapy Combined Treatment To Chronic Myelogenous Leukemia In Blastic Phase Patients
114.	Relationship Between EGFR Mutations And Clinicopathological Features In NSCLC And Prognostic Analysis Of TKI Treatment
115.	Anti-tumor Activity Of High-dose EGFR Tyrosine Kinase Inhibitor Combined With Docetaxel Against Lung Cancer With EGFR Wild Type In Vivo
116.	A Preliminary Study Of Lung Adenocarcinoma Linyi Region Of The EGFR Gene Mutation Status
117.	Design And Synthesis Of Hypoxic Tissue Targeted Anilinoquinazoline Tyrosine Kinase Inhibitors
118.	Synthesis And Process Optimization Of Nilotinib
119.	The Correlation Between EGFR Mutation Status And EGFR-TKI Efficacy In Non-small Cell Lung Cancer
120.	Preclinical Pharmacokinetics Of A New Anticancer Drug Of Tyrosine-kinase Inhibitor
<<First <Prev Next> Last>> Jump to